Stage 4 pancreatic cancer treatment centers on combination chemotherapy (FOLFIRINOX, gemcitabine/nab-paclitaxel), single-agent regimens, targeted therapies for actionable mutations, and thorough palliative care, selected primarily by performance status (ECOG 0-1 vs. 2 vs. 3-4) and treatment goals (life extension vs. Quality of life). Key Takeaways FOLFIRINOX and gemcitabine/nab-paclitaxel serve as first-line chemotherapy options, selected by ECOG performance status, age, and

Stage 4 pancreatic cancer represents advanced disease where cancer has spread beyond the pancreas to distant organs, requiring comprehensive treatment strategies that balance disease control with quality of life. TL;DR FOLFIRINOX and gemcitabine plus nab-paclitaxel remain first-line chemotherapy options for stage 4 pancreatic cancer, with median survival ranging from 6.8 to 11.1 months depending on regimen and patient fitness [1] Dr. Bharat Patodiya provides comprehensive tre